Similarly, GEMMs, which incorporate clinically relevant genetic alterations identified in lung cancer patients—such as KRAS, p53, and ALK mutations—develop tumors orthotopically, yet often exhibit longer latency periods and sporadic metastases [729–731], which limits their experimental feasibility. This evidence concerns the gene KRAS and lung carcinoma.